PNS108 Proposal for a Core Evaluation Framework of Value Added Medicines
Objectives Through incremental innovation by repositioning, reformulating and combining of off-patent pharmaceuticals, value added medicines (VAMs) offer potential benefits at affordable R&D costs. Current evaluation frameworks are primarily designed for de novo pharmaceuticals, consequently the mismatch between evidence requirements by public decision-makers and the evidence generated by manufacturers prevents exploiting the full societal benefits of…